Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice
European Journal of Immunology · 2023
DOI: 10.1002/eji.202250182 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Ping Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Ministry of Education Key Laboratory of Child Development, and Disorders, National Clinical Research Center for Child H…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Melanoma, Experimental. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Hypoxia‐inducible factor 1 alpha (HIF1α), under hypoxic conditions, is known to play an oxygen sensor stabilizing role by exerting context‐ and cell‐dependent stimulatory and inhibitory functions in immune cells. Nevertheless, how HIF1α regulates T cell differentiation and functions in tumor settings has not been elucidated. Herein, we demonstrated that T‐cell‐specific deletion of HIF1α improves the inflammatory potential and memory phenotype of CD8 + T cells. We validated that T cell‐specific HIF1α ablation reduced the B16 melanomas development with the indication of ameliorated antitumor immune response with enhanced IFN‐γ + CD8 + T cells despite the increase in the Foxp3 + regulatory T‐cell population. This was further verified by treating tumor‐bearing mice with a HIF1α inhibitor. Results indicated that HIF1α inhibitor also recapitulates HIF1α ablation effects by declining tumor growth and enhancing the memory and inflammatory potential of CD8 + T cells. Furthermore, a combination of Treg inhibitor with HIF1α inhibitor can substantially reduce tumor size. Collectively, these findings highlight the notable roles of HIF1α in distinct CD8 + T‐cell subsets. This study suggests the significant implications for enhancing the potential of T cell‐based antitumor immunity by combining HIF1α and Tregs inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Ministry of Education Key Laboratory of Child Development, and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Techn…
- Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), Shenzhen, P. R. China.
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shenzhen Science and Technology Program
- Natural Science Foundation of Chongqing
- Entrepreneurship and Innovation Support Program of Program of Chongqing for Overseas Scholars
- National Key Research and Development Program of China
Zitieren
APA
Wei, P., Kou, W., Riaz, F., Zhang, K., Fu, J., & Pan, F. (2023). Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice. European Journal of Immunology. https://doi.org/10.1002/eji.202250182
Vancouver
Wei P, Kou W, Riaz F, Zhang K, Fu J, Pan F. Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice. European Journal of Immunology. 2023. doi:10.1002/eji.202250182
BibTeX
@article{Wei2023,
author = {Wei, Ping and Kou, Wei and Riaz, Farooq and Zhang, Kaimin and Fu, Juan and Pan, Fan},
title = {Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice},
journal = {European Journal of Immunology},
year = {2023},
doi = {10.1002/eji.202250182}
}
EUVIMED